Background: Common variable immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency (PID). It is characterized by heterogeneous clinical manifestations and defects in B cells and T cells. In the present study, we investigated helper T (T H ) cell subsets and regulatory T (Treg) cells and their related cytokines and transcription factors in CVID patients with no definitive genetic diagnosis. Methods: The study population comprised 13 CVID patients and 13 healthy controls. Mutation analysis was performed using whole exome sequencing in CVID patients to rule out monogenic PIDs. T H subsets and Treg were analyzed using flow cytometry. The expression of determinant cytokines (IFN-γ, IL-17, IL-22, and IL-10) and cell subset specific transcription factors was evaluated before and after stimulation. Results: The main clinical presentations of these patients were infections only and lymphoproliferative phenotypes. No autoimmune or allergy phenotypes were recorded. The frequencies of CD4 + T cells, T H 17, and Treg cells were significantly reduced in CVID patients; however, T H 1, T H 1-like T H 17, and T H 22 subsets were normal. After stimulation, expression of retinoic-acid-orphan-receptor-C (RORC), runtrelated transcription factor 1 (RUNX1), IL17, and IL10 was significantly lower in CVID patients than in the healthy controls. Moreover, the concentration of IL-17 and IL-10 in the cell culture supernatants of stimulated CD4 + T cells was lower in CVID patients than in healthy controls.
Introduction

Common variable immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency (PID).
It is characterized by heterogeneous clinical/immunologic manifestations [1] , including susceptibility to recurrent infections, hypogammaglobulinemia, and reduced specific antibody response to protein and polysaccharide antigens [2] . The underlying causes of CVID are largely unknown. Genetic mutations can be identified as the cause of disease in approximately 10%-20% of patients depending on the ethnicity and population structure of the cohort [3] . The genes involved include mainly the members of the B-cell coreceptor complex, transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI), B cell-activating factor receptor (BAFFR), inducible costimulator (ICOS), and lipopolysaccharide responsive beige-like anchor (LRBA) genes. Although these new monogenic defects share clinical phenotypes with CVID, they could be considered distinct PIDs with a CVID-like phenotype [3] [4] [5] . However, a definite molecular genetic diagnosis has not been made in more than 80% of clinically diagnosed CVID patients, and the cause of their disease remains unknown.
In addition to recurrent infections, CVID patients have a wide range of clinical manifestations, including autoimmune disease, allergic diseases, enteropathy, and lymphoproliferative disorders [6] [7] [8] . Several studies reported that except for severe B-cell deficiency, T-cell abnormalities may also be involved in the pathogenesis of immune dysregulation in CVID patients. The T-cell defects that characterize CVID include CD4 + T-cell deficiency, defects in regulatory T cell (Treg) counts and function, decreased lymphocyte proliferation, uncontrolled T-cell polarization, elevated levels of T-cell activation markers, and abnormal cytokine production [9] [10] [11] [12] [13] .
Although the abnormality of CD4 + T cells has been linked to clinical presentations of CVID including lymphoproliferative and autoimmune disorders [11] , no studies have examined the frequencies and functional status of T H subsets and their intricate balance with Treg cells. In the present study, we evaluated the proportion and frequencies of peripheral T H 1, T H 1-like T H 17, T H 17, T H 22, and CD127 low/-Treg cells, as well as their determinant cytokines and transcriptional factors in CVID patients with no definitive genetic diagnosis.
Patients and Methods
Patients
The study population comprised available CVID patients who were referred to the PID Clinic at the Children's Medical Center affiliated to Tehran University of Medical Sciences, Tehran, Iran. Thirteen healthy individuals with no history of immune disorders (eg, severe infection, allergy, autoimmunity, or malignancy) were selected as a healthy control (HC) group. The study was approved by the Ethics Committee of Tehran University of Medical Sciences (ID number: IR.TUMS. REC.1394.696), and written informed consent was obtained from all participants and/or their parents. Demographic and clinical data were collected from the Iranian national registry of PID patients [14] , which was updated at monthly visits and thoroughly reviewed by clinical immunologists. The inclusion criteria were a definitive diagnosis of CVID, as defined by the European Society for Immunodeficiencies (https://esid.org/ Education/Diagnostic-Criteria-PID) [2] , and regular therapy with intravenous Ig (IVIG).
Whole Exome Sequencing
Genomic DNA was extracted from whole blood from each proband, randomly fragmented, amplified by ligation-mediated polymerase chain reaction (PCR), and captured and sequenced according to the manufacturer's protocol, as described previously [15] . After raw image file processing, sequences were generated and aligned to the human genome reference (UCSC hg 19 version; build 37.1). We followed the analysis protocol for whole exome sequencing designed by the BGIShenzhen/Karolinska Institute as described previously [16] . Patients with a tentative diagnosis of CVID and an identified mutation within 373 known monogenic PID genes (Table S1) were excluded from this study [15, 16] . Therefore, the study population comprised 13 CVID patients with no definitive genetic diagnosis.
Cell Isolation and Purification of CD4 + T Cells
The blood samples were collected 4 weeks after the IVIG infusion in heparin-containing tubes. Lymphocyte counts were performed using the Sysmex KX-21N Hematology Analyzer redujo significativamente en los pacientes con CVID; sin embargo, las poblaciones de Th1, Th1similares a Th17 y Th 22 fueron normales. Después de la estimulación, la expresión de los genes receptor huérfano tipo C del ácido retinoico (RORC) y del factor de transcripción 1 relacionado con Runt (RUNX1), IL-17 e IL-10 fue significativamente menor en los pacientes con IDCV en comparación con los controles sanos. También se objetivó una menor concentración de IL-17 e IL-10 en los sobrenadantes del cultivo de linfocitos T CD4 + estimulados de los pacientes con CVID, respecto a los HC. Conclusiones: Nuestros hallazgos demuestran que en los pacientes con CVID sin un diagnóstico genético definitivo y sin trastornosRT-PCR, total RNA was extracted from cultured cells using the RNeasy Mini Kit (Qiagen) and reversed transcribed into cDNA using the Takara kit (Takara) according to the manufacturer's instructions with some modifications. Expression levels of IFNG, IL17, IL22, IL10, T-box transcription factor (TBET), runt-related transcription factor 1 (RUNX1), RAR-related orphan receptor C (RORC), aryl hydrocarbon receptor (AHR), and FOXP3 genes were measured with quantitative RT-PCR using SYBR Green PCR Master Mix (Takara) with specific primers (Table S2 ). Quantitative gene expression data were normalized relative to levels of GAPDH (glyceraldehyde-3-phosphate dehydrogenase).
Cytokine Assay
CD4
+ T cells were harvested and brought to a final concentration of 3×10 5 /mL in 24-well plates before being stimulated with anti-CD3 mAb and anti-CD28 mAb using the method mentioned in the previous section. Unstimulated cells were used as controls for each experiment. Supernatants were collected after 48 hours, and cytokine production (IFN-γ, IL-17, IL-22, and IL-10) was evaluated using quantitative enzyme-linked immunosorbent assay (ELISA) with the commercial human ELISA Ready-SET-Go kits (eBioscience) according to the manufacturer's instructions. The sensitivity of detection was 2 pg/mL for IL-10, 4 pg/mL for IFN-γ and IL-17, and 8 pg/mL for IL-22.
Statistical Analysis
Values were expressed as frequency (number and percentage) and median (IQR), as appropriate. The Shapiro-Wilks test was used to check normality. A parametric or nonparametric test was (Sysmex Corporation). Peripheral blood mononuclear cells (PBMCs) were obtained from both patients and HCs using lymphocyte separation medium (Lymphosep, Biosera) and resuspended in RPMI medium (Lymphosep, Biosera) supplemented with 10% fetal bovine serum (Lymphosep, Biosera), penicillin (100 IU), and streptomycin (100 μg/mL) (Biosera, Ringmer) for immunophenotyping and CD4
+ T-cell isolation. The viability of isolated PBMCs was more than 97%, as assessed using the Trypan blue viability test. CD4 + T cells were purified from PBMCs with a human CD4 + T Cell Isolation Kit (Miltenyi Biotec) by depletion of non-CD4 + T cells (negative selection). The purity of CD4 + T cells was routinely more than 95% based on flow cytometry.
Flow Cytometry Analysis
For intracellular staining of T H cells, 1×10 6 PBMCs were stimulated with phorbol myristate acetate (PMA, 50 ng/mL, Sigma) and ionomycin (1 μg/mL, Sigma) for 5 hours in RPMI medium at 37°C in a 5% CO 2 humidified atmosphere in the presence of Brefeldin A (BFA, 10 μg/mL, eBioscience). The stimulated cells were washed with cold PBS, and cell surface staining antibodies (anti-CD4 PerCP-cy5.5, clone OKT4) (eBioscience) were added and incubated in the dark at 4°C for 30 minutes. Alternatively, for evaluation of Tregs, unstimulated PBMCs were stained using surface antibodies (anti-CD4 PerCP-cy5. 
FoxP3
+ cells. Isotype-matched control antibodies and fluorescence minus one (FMO) control stains were used to determine background levels of staining.
Quantitative Real-time Polymerase Chain Reaction (RT-PCR)
CD4
+ T cells were harvested and brought to a final concentration of 2×10 6 /mL in 24-well plates that were precoated with 3 μg/mL anti-CD3 mAb. Moreover, 2 μg/mL anti-CD28 mAb was added concurrently and incubated in RPMI medium at 37°C in a 5% CO 2 humidified atmosphere. Stimulated cells were collected after 18 hours and washed twice with PBS. For 
Results
Characteristics and Clinical Phenotypes of CVID Patients
To determine the frequency of different subsets of CD4 and mucosal candidiasis and biopsy-proven enteropathy were observed in 1 patient each (7.7%). A history of severe infection (meningitis, septicemia, and osteomyelitis), granuloma, autoimmunity, allergic symptoms, and malignancy were not recorded in any of these CVID patients.
Frequency of T H Subsets in CVID Patients
In order to compare the distribution of peripheral T H subsets in CVID patients and HCs, we examined the relative abundance and absolute counts of T H 1 (IFN-γ + IL-17 -), T H 17 
T-cell deficiency (defined as CD4
+ T cells/µL at 2-6 years <300, 6-12 years <250, and >12 years <200) [9] was found in 1 CVID patient.
There were no significant differences in the median percentages of T H 
Decreased Percentage of Treg Cells in CVID Patients
The frequency of Treg cells (CD4 + CD25 + FoxP3 + ) in the peripheral blood of CVID patients and HCs was evaluated. We further analyzed the percentages of CD127 expression on Treg cells. The gating procedure and typical dot plots for the expression of circulating Treg cells are depicted in Figure  S1D- (Table S3) .
Cytokines and Transcription Factor mRNA Expression
Transcription levels of TBET, RORC, AHR, RUNX1, FOXP3 and of the cytokine genes IFNG, IL17, IL22, and IL10 were evaluated for the CD4 + T cells of CVID patients and HCs with and without stimulation by anti-CD3 and anti-CD28. The results showed that in the absence of stimulation, the gene expression levels of TBET, IFNG, and IL22 in CVID patients were significantly higher than in HCs, whereas the transcription levels of RORC and RUNX1 were significantly lower than in HCs (Figure 2) . Similarly, after stimulation, the expression levels of RORC, RUNX1, IL17, and IL10 in CVID patients were significantly lower than in the HC group (Figure 2) . Moreover, after stimulation of CD4 + T cells, the median fold change in TBET was higher, while FOXP3 was lower in CVID patients than in HCs. However, the differences were not significant.
Cytokine Production by CD4 + T Cells
To test the function of different subsets of CD4 + T cells, we measured the concentrations of the corresponding predominant cytokines-IFN-γ, IL-17, IL-22, and IL-10-in cell culture supernatants. There was no significant difference in cytokine production in the absence of stimulation ( Figure 3A) . Finally, in CVID patients with the lymphoproliferative clinical phenotype, the frequency of CD4 + T cells, T H 1, T H 17, T H 22, and Treg cells and their determinant cytokines (IFN-γ, IL-17, IL-22, and IL-10) was lower when T H 1-like T H 17 cell levels were higher than those of CVID patients with only the infectious clinical phenotype. However, the differences were not significant.
Discussion
Several studies reported that the typical clinical features of CVID are respiratory tract infection, enteropathy, and lymphoproliferative and autoimmune disorders [6, 17, 18] . In a study by Resnick et al [17] , 94% of 473 patients had a history of infection, mostly respiratory tract infections, although autoimmune disease was also diagnosed in 28.6%, bronchiectasis in 11.2%, and enteropathy in 15.4%. In a study by Chapel et al [6] enteropathy was reported in 9%, autoimmunity in 21.6%, and splenomegaly in 30% of patients. Finally, Gathmann et al [19] reported that the clinical picture of 2212 CVID patients comprised autoimmunity in 29%, splenomegaly in 26%, bronchiectasis in 23%, and enteropathy in 9%. However, none of these studies performed a full genetic investigation using next-generation sequencing. Thus, the clinical phenotypes could be biased in these studies by the finding of monogenic PID mimicking the immunologic profile of CVID. In the present study, the clinical complications of CVID patients after excluding all known monogenic PIDs were less numerous than in the abovementioned studies: 77% had a history of respiratory tract infection, 30.8% had splenomegaly, and 7.7% had biopsy-proven enteropathy. None of the patients had a history of autoimmunity. However, in our previous study on non-genetically evaluated CVID patients, there was a higher frequency of clinical complications, including autoimmunity in 40.3%, enteropathy in 15.3%, and splenomegaly in 40.3% [11] . The fewer clinical symptoms (particularly autoimmunity) in our study are evident in comparison with the previous study. We suggest that the lower frequency of clinical symptoms in our study is related to differences in the inclusion criteria. Obviously, mutation analysis reveals a higher percentage of monogenic disorders such as LRBA, CD27, and CD70 deficiencies, which have more severe clinical presentations, including autoimmunity, enteropathy, and lymphoproliferative diseases [20] [21] [22] . Therefore, the remaining CVID patients in whom mutations are not found are patients with milder clinical symptoms. Importantly, the lymphoproliferative phenotype was the major clinical complications among patients whose diagnosis remained unresolved.
In the present study, CD4 + T-cell counts were low in 53.8% of unresolved cases of CVID. Similar findings have been reported elsewhere, and imbalance of some subsets was correlated with severity of immune dysregulation (autoimmunity, lymphoproliferative disorder, and organ inflammation) [9, 11] . We showed no significant differences in the percentages of T H 1, T H 1-like T H 17, and T H 22 cells in CVID patients compared with HCs, although we did find differences for T H 17. In a study by Coraglia et al [23] , follicular CD4 + T helper cells were more numerous in CVID patients than in HCs, particularly in those with severe clinical features of inflammation and autoimmunity. Moreover, it has been reported that in CVID patients with immune dysregulation, CD4 + T-cell differentiation was strongly skewed toward a T H 1 phenotype, consistent with the higher IFN-γ production and impaired IL-4 signaling in CD4 + T cells [24] [25] [26] . Finally, Kutukculer et al [27] reported that T H 1 cells are more involved in the pathogenesis of CVID than T H 2 cells. As mentioned, in contrast with previous studies, we did not observe any differences in T H 1 frequency in CVID compared with HCs, although in previous studies, the higher frequency of T H 1 was correlated with the severe clinical features of inflammation and autoimmunity, which were rare in our CVID patients. Although the lack of similar studies on the frequency of T H 1-like T H 17 and T H 22 cells in CVID patients prevents us from comparing our findings, several studies reported a higher frequency of this subset in nonimmunodeficient patients with autoimmunity and enteropathy [28, 29] . Recently, it was reported that pathogenic T H 17 cells can give rise to T H 1-like T H 17 cells that are implicated in the development of autoimmune diseases and enteropathy [30] . On the other hand, in a previous study, we found that LRBA patients have higher T H 1-like T H 17 cell counts than HCs and that the frequency of this subset in LRBA patients with autoimmunity and enteropathy was higher than in patients without these complications (unpublished data). Therefore, homeostasis of these subsets in the CVID patients we report corresponds to the rare episodes of autoimmunity and enteropathy. We found that the percentages of T H 17 cells, transcripts of RORC, and IL17 in CVID were significantly lower than in HCs. This finding has also been reported in previous studies. Barbosa et al [31] reported a reduced frequency of circulating T H 17 cells in CVID patients. Ganjalikhani-Hakemi et al [32] found that the transcript levels of IL17 and RORC2 in CVID patients were considerably lower than in HCs. Moreover, Berron-Ruiz et al [33] observed lower levels of IL-17 in CVID patients. However, the high frequency of T H 17 cells and IL-17 was associated with autoimmunity in several studies. This phenomenon is absent in CVID, probably owing to high plasticity and/or apoptosis of T H 17 cells in the special condition of CVID.
Reduced frequency of Treg cells is another defect of CVID patients [26] . Arandi et al [12] showed that Treg frequency and suppressive function were impaired in CVID patients. Yu et al [34] also reported a lower suppressive function of Tregs in CVID patients with autoimmune disease than in CVID patients with no autoimmune disease. In the present study, consistent with previous reports, we found that total Treg cell and CD127 low/-Treg cell counts were significantly lower in CVID patients without monogenic disorders. However, Coraglia et al [23] proposed that Treg percentages were similar in CVID patients and in HCs. On the other hand, the correlation between Treg deficiency and clinical manifestation is contradictory in few studies. Kofod-Olsen et al [35] observed that the frequency of Tregs is correlated with clinical manifestations, including autoimmunity, and splenomegaly. Melo et al [26] also stratified CVID patients based on autoimmune status but did not record any association with Treg frequency. Kutukculer et al [27] reached the same conclusion in their study on the percentages and absolute numbers of Treg cells, which did not differ significantly between CVID patients and HCs, or between severe and moderate forms of CVID.
In conclusion, apart from antibody deficiency, Treg and T H 17 subset deficiencies are an intrinsic characteristic of CVID patients with no known monogenic disorder confirmed in whole exome sequencing. Given that several potential polygenic and epigenetic etiologies may underlie pathogenesis in these patients, other next-generation sequencing technologies such as RNA sequencing and epigenetic studies (DNA methylation, histone modification, and noncoding RNA-associated gene silencing) can further contribute to our understanding of the complexities of CVID.
